Evidence map›Paper›PMID 36258195›Full record

ReviewCancer cell international2022

Strategies to overcome the main challenges of the use of exosomes as drug carrier for cancer therapy.

Bashdar Mahmud Hussen, Goran Sedeeq Hama Faraj, Mohammad Fatih Rasul, Hazha Jamal Hidayat, Abbas Salihi, Aria Baniahmad, Mohammad Taheri, Soudeh Ghafouri-Frad

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer cell international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
8.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 101 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Current trends in exosomes as therapeutic drug delivery systems.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Bashdar Mahmud HussenDepartment of Pharmacognosy, College of Pharmacy, Hawler Medical University, Erbil, Kurdistan Region, Iraq.
Goran Sedeeq Hama FarajCollege of Medicine, Department of Medical Laboratory Sciences, Komar University of Science and Technology, Sulaymaniyah, Iraq.
Mohammad Fatih RasulDepartment of Pharmaceutical Basic Science, Faculty of Pharmacy, Tishk International University, Erbil, Kurdistan Region, Iraq.
Hazha Jamal HidayatDepartment of Biology, College of Education, Salahaddin University, Erbil, Kurdistan Region, Iraq.
Abbas SalihiDepartment of Biology, College of Science, Salahaddin University, Erbil, Kurdistan Region, Iraq.
Aria BaniahmadInstitute of Human Genetics, Jena University Hospital, Jena, Germany.
Mohammad TaheriInstitute of Human Genetics, Jena University Hospital, Jena, Germany. mohammad.taheri@uni-jena.de.
Soudeh Ghafouri-FradDepartment of Medical Genetics,, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. s.ghafourifard@sbmu.ac.ir.
Jena University Hospital · DESalahaddin University-Erbil · IQHawler Medical University · IQKomar University of Science and Technology · IQShahid Beheshti University of Medical Sciences · IRTishk International University · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosomes are naturally occurring nanosized particles that aid intercellular communication by transmitting biological information between cells. Exosomes have therapeutic efficacy that can transfer their contents between cells as natural carriers. In addition, the exosomal contents delivered to the recipient pathological cells significantly inhibit cancer progression. However, exosome-based tumor treatments are inadequately precise or successful, and various challenges should be adequately overcome. Here, we discuss the significant challenges that exosomes face as drug carriers used for therapeutic targets and strategies for overcoming these challenges in order to promote this new incoming drug carrier further and improve future clinical outcomes. We also present techniques for overcoming these challenges.

Indexed as

Cancer therapyDrug carrierExosomal delivery challengesExosome

Identifiers

PMID36258195
PMCPMC9580186
OpenAlexW4306743879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.